Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | MAOB | P27338 | 4/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | HTR2C | P28335 | 6/20 | 0.34 |
| ▸ | HTR2B | P41595 | 4/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.31 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2585106 | 0.77 | MAOA (0.38) | TRPA1MAOAMAOBNFKB1HTR2A | |
| SCHEMBL8404363 | 0.77 | MAOA (0.38) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL6949814 | 0.74 | MAOA (0.38) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL3173028 | 0.74 | MAOA (0.40) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL2269866 | 0.74 | KDM4E (0.47) | MAOAMAOBNFKB1HTR2AHTR2C | |
| SCHEMBL24036411 | 0.74 | MAOA (0.36) | TRPA1MAOAMAOBNFKB1HTR2A | |
| SCHEMBL18876065 | 0.74 | MAOA (0.36) | TRPA1MAOAMAOBNFKB1HTR2A | |
| SCHEMBL5986568 | 0.74 | MAOA (0.36) | TRPA1MAOAMAOBNFKB1HTR2A | |
| SCHEMBL29473759 | 0.74 | CYP2A6 (0.39) | TRPA1MAOAMAOBNFKB1HTR2A | |
| SCHEMBL17841499 | 0.74 | CYP2A6 (0.39) | TRPA1MAOAMAOBNFKB1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021195183-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE | EXO THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-0901483-B1 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LTD (GB) | 2003-07-09 | — | — | EP | disclosed |
| US-5981572-A | Benzofurans and benzopyrans as chronobiological agents | GLAXO WELLCOME INC. (US) | 1999-11-09 | — | — | US | disclosed |
| EP-0901483-A2 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LIMITED (GB) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043272-A2 | BENZOFURANS AND BENZOPYRANS AS CHRONOBIOLOGICAL AGENTS | GLAXO GROUP LIMITED (GB) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | TRPA1 2870/4885MAOA 2692/4885MAOB 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.